Company Overview and News

90
Tracking Dan Loeb's Third Point Portfolio - Q2 2018 Update

2018-08-12 seekingalpha - 7
Dan Loeb's 13F portfolio value increased from $13.32B to $14.35B this quarter. The number of positions decreased from 40 to 38.
ATHTF STZ.B TWX CRM DOW DOV MELI PBF TPRE WP KDMN STZ UTX BKI TWC PVH DVMT FPAC.U GOOGL MSFT APY MHK TPNTF GRBK FB DOV.WI LEN NXPI PYPL NFLX BAX GOOG LEN.B MPC PAGS ADBE SPGI EGN MON ICE SHY CWH EA WYNN ANTM DWDP BID BLK V DHR ANTX

 
APY / Apergy Corporation FORM 8-K (Current Report)

2018-08-10 sec.gov
Document UNITED STATES
APY

1
3 Notable Dividend Increases To Consider

2018-08-08 seekingalpha
I narrow the list down to companies that have a 10-year track record of annual increases.
DOV.WI ITW DOV IFF APY

 
APY / Apergy Corporation FORM 10-Q FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2018 (Quarterly Report)

2018-08-06 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
APY

 
Apergy Corp 2018 Q2 - Results - Earnings Call Slides

2018-07-26 seekingalpha
The following slide deck was published by Apergy Corp in conjunction with their 2018 Q2 earnings call.
APY.WI APY

 
Apergy Reports Second Quarter 2018 Results

2018-07-25 globenewswire
THE WOODLANDS, Texas, July 25, 2018 (GLOBE NEWSWIRE) -- Apergy Corporation (“Apergy”) (NYSE:APY) today reported net income in the second quarter of 2018 of $22.2 million, compared to net income of $18.8 million in the second quarter of 2017. Diluted earnings per share in the second quarter of 2018 was $0.29 and include total after-tax charges of $7.2 million, or $0.09 per diluted share, related to spin-off and other restructuring activities.
APY.WI DOV.WI DOV APY

 
Dover's (DOV) CEO Richard Tobin on Q2 2018 Results - Earnings Call Transcript

2018-07-19 seekingalpha
Good morning and welcome to Dover's Second Quarter 2018 Earnings Conference Call. Speaking today are Richard J. Tobin, President and Chief Executive Officer; Brad Cerepak, Senior Vice President and CFO; and Paul Goldberg, Vice President of Investor Relations.
APY.WI DOV APY

115
Oakmark Equity And Income Fund: Second Quarter 2018

2018-07-11 seekingalpha
The Equity and Income Fund earned 0.2% in the quarter, while the Lipper Balanced Fund Index, the Fund’s performance benchmark, gained 1.1%.
PM DOV.WI NOV TEL CVS FNF BAC CHTR APY.WI FNFV DOV GM ORCL LBRDB BAC C AAL BHGE COMM MA ARNC TWC LBRDK BHI CGBBW OCLCF JLL LBRDA FL APY UNH

 
Apergy Announces Second Quarter 2018 Earnings Release and Conference Call Schedule

2018-07-05 globenewswire
THE WOODLANDS, Texas, July 05, 2018 (GLOBE NEWSWIRE) -- Apergy Corporation (“Apergy”) (NYSE:APY) announced today that it will release its second quarter 2018 operating results on Wednesday, July 25, 2018 after the market closes. The Company has scheduled a conference call for Thursday, July 26, 2018 at 8 a.m. Central Time (9 a.m. Eastern Time) to discuss the results.
APY.WI APY

2
Over 60 Years Of Dividend Increases, A Big Spin-Off And Hope

2018-06-27 seekingalpha
Now that DOV has spun-off its oil & gas business (Apergy), it will show more stable returns.
APY.WI DOV APY

2
Dover: The Worst Performing Dividend Champion Of 2018

2018-06-25 seekingalpha
The stock has been the worst performing Dividend Champion of 2018, falling 28.1% year to date.
MGRC DOV APY

28
Apergy to Attend Wells Fargo West Coast Energy Conference

2018-06-08 globenewswire
THE WOODLANDS, Texas, June 08, 2018 (GLOBE NEWSWIRE) -- Apergy Corporation (“Apergy”) (NYSE:APY) announced today that Sivasankaran "Soma" Somasundaram, President and Chief Executive Officer, and Jay Nutt, Senior Vice President and Chief Financial Officer, will attend and meet with investors at the Wells Fargo 2018 West Coast Energy Conference in San Francisco, California on June 12, 2018. The presentation to be used in the investor meetings will be available on Tuesday, June 12, 2018, prior to the commencement of the meetings under the “Investors – Media Files” tab of our website at http://www.
WFC WFCNP APY.WI APY

 
APY / Apergy Corporation FORM 8-K (Current Report)

2018-06-05 sec.gov
Document UNITED STATES
APY

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to APY / Apergy Corporation on message board site Silicon Investor.

Group Therapy Group Therapy Group Therapy The Promising, Cheap, And Growing Cell Therapy Arena Continu The Promising, Cheap, And Growing Cell Therapy Arena Continu The Promising, Cheap, And Growing Cell Therapy Arena Continu
U.S. Physical Therapy (USPH) U.S. Physical Therapy (USPH) U.S. Physical Therapy (USPH) Vion (formerly Oncorx) interesting play on Gene Therapy Vion (formerly Oncorx) interesting play on Gene Therapy Vion (formerly Oncorx) interesting play on Gene Therapy
Gene therapy Gene therapy Gene therapy Advanced Biotherapy Inc. (ADVB) Advanced Biotherapy Inc. (ADVB) Advanced Biotherapy Inc. (ADVB)
Cyberonics (cybx) epilepsy therapy recommonded Cyberonics (cybx) epilepsy therapy recommonded Cyberonics (cybx) epilepsy therapy recommonded EDAP TMS S.A. (EDAPY) EDAP TMS S.A. (EDAPY) EDAP TMS S.A. (EDAPY)
Urine Used as a Natural Therapy for Diseases Urine Used as a Natural Therapy for Diseases Urine Used as a Natural Therapy for Diseases tech. enhancements -- radioisotopes, therapy/diagnosis tech. enhancements -- radioisotopes, therapy/diagnosis tech. enhancements -- radioisotopes, therapy/diagnosis